Logo image of PPBT

PURPLE BIOTECH LTD-ADR (PPBT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PPBT - US74638P1093 - ADR

0.6773 USD
-0.03 (-4.02%)
Last: 12/29/2025, 8:14:04 PM
0.6501 USD
-0.03 (-4.02%)
After Hours: 12/29/2025, 8:14:04 PM
Fundamental Rating

1

PPBT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. PPBT may be in some trouble as it scores bad on both profitability and health. PPBT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PPBT had negative earnings in the past year.
In the past year PPBT has reported a negative cash flow from operations.
In the past 5 years PPBT always reported negative net income.
In the past 5 years PPBT always reported negative operating cash flow.
PPBT Yearly Net Income VS EBIT VS OCF VS FCFPPBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.32%, PPBT is in the better half of the industry, outperforming 69.11% of the companies in the same industry.
PPBT's Return On Equity of -9.92% is fine compared to the rest of the industry. PPBT outperforms 74.35% of its industry peers.
Industry RankSector Rank
ROA -8.32%
ROE -9.92%
ROIC N/A
ROA(3y)-34.7%
ROA(5y)-32.74%
ROE(3y)-42.11%
ROE(5y)-37.99%
ROIC(3y)N/A
ROIC(5y)N/A
PPBT Yearly ROA, ROE, ROICPPBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PPBT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PPBT Yearly Profit, Operating, Gross MarginsPPBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, PPBT has more shares outstanding
The number of shares outstanding for PPBT has been increased compared to 5 years ago.
PPBT has a better debt/assets ratio than last year.
PPBT Yearly Shares OutstandingPPBT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PPBT Yearly Total Debt VS Total AssetsPPBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

PPBT has an Altman-Z score of -3.94. This is a bad value and indicates that PPBT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.94, PPBT is not doing good in the industry: 60.73% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.00 indicates that PPBT is not too dependend on debt financing.
The Debt to Equity ratio of PPBT (0.00) is better than 60.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.94
ROIC/WACCN/A
WACCN/A
PPBT Yearly LT Debt VS Equity VS FCFPPBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.78 indicates that PPBT should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.78, PPBT is doing worse than 65.97% of the companies in the same industry.
A Quick Ratio of 1.78 indicates that PPBT should not have too much problems paying its short term obligations.
The Quick ratio of PPBT (1.78) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
PPBT Yearly Current Assets VS Current LiabilitesPPBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.67% over the past year.
EPS 1Y (TTM)85.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PPBT Yearly Revenue VS EstimatesPPBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 200K 400K 600K 800K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PPBT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PPBT Price Earnings VS Forward Price EarningsPPBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PPBT Per share dataPPBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PPBT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PURPLE BIOTECH LTD-ADR

NASDAQ:PPBT (12/29/2025, 8:14:04 PM)

After market: 0.6501 -0.03 (-4.02%)

0.6773

-0.03 (-4.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14
Earnings (Next)03-03 2026-03-03
Inst OwnersN/A
Inst Owner Change132.55%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.12M
Revenue(TTM)N/A
Net Income(TTM)-3.25M
Analysts0
Price TargetN/A
Short Float %2.88%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB 1.24
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS3.63
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.32%
ROE -9.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.7%
ROA(5y)-32.74%
ROE(3y)-42.11%
ROE(5y)-37.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -3.94
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)38.32%
Cap/Depr(5y)46.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y68.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.53%
OCF growth 3YN/A
OCF growth 5YN/A

PURPLE BIOTECH LTD-ADR / PPBT FAQ

Can you provide the ChartMill fundamental rating for PURPLE BIOTECH LTD-ADR?

ChartMill assigns a fundamental rating of 1 / 10 to PPBT.


Can you provide the valuation status for PURPLE BIOTECH LTD-ADR?

ChartMill assigns a valuation rating of 0 / 10 to PURPLE BIOTECH LTD-ADR (PPBT). This can be considered as Overvalued.


How profitable is PURPLE BIOTECH LTD-ADR (PPBT) stock?

PURPLE BIOTECH LTD-ADR (PPBT) has a profitability rating of 1 / 10.